Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,467Revenue $M3.6Net Margin (%)-3,237.2Altman Z-Score44.4
Enterprise Value $M2,110EPS $-1.3Operating Margin %-3,334.9Piotroski F-Score5
P/E(ttm)--Beneish M-Score-1.8Pre-tax Margin (%)-3,237.2Higher ROA y-yY
Price/Book6.610-y EBITDA Growth Rate %--Quick Ratio17.2Cash flow > EarningsY
Price/Sales6185-y EBITDA Growth Rate %--Current Ratio17.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-42.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M98.5ROIC % (ttm)-786.6Gross Margin Increase y-yN

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJoel Greenblatt 2015-03-31 Buy 0.01%$18.29 - $31.78
($23.85)
$ 25.055%New holding35,223
CLDXFirst Eagle Investment 2014-12-31 Add0.01%$12.55 - $20.93
($16.61)
$ 25.0551%Add 123.82%559,542
CLDXFirst Eagle Investment 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 25.0573%New holding250,000
CLDXFirst Eagle Investment 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 25.05-2%Sold Out0
CLDXFirst Eagle Investment 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 25.05-2%Reduce 75.45%135,000
CLDXFirst Eagle Investment 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 25.0591%Reduce 45.89%665,560
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 25.05471%Sold Out0
CLDXFirst Eagle Investment 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 25.05471%Add 260.87%1,660,000
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 25.05526%New holding803,200
CLDXFirst Eagle Investment 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 25.05526%Add 360.00%460,000
CLDXFirst Eagle Investment 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 25.05828%Reduce 71.43%100,000
CLDXFirst Eagle Investment 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 25.05568%New holding350,000
CLDXFirst Eagle Investment 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 25.05408%Sold Out0
CLDXFirst Eagle Investment 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 25.05424%New holding100,000
CLDXFirst Eagle Investment 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 25.05294%Sold Out0
CLDXFirst Eagle Investment 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 25.05193%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CATLIN AVERY WSr. VP & CFO 2015-06-15Sell25,000$24.591.87view
van den Broek RichardDirector 2014-12-17Sell0$01.87view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.52.24view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.52.24view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.52.24view
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.52.24view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.5902view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.41939.42view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.39948.12view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74569.79view

Quarterly/Annual Reports about CLDX:

News about CLDX:

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
comment on CLDX Mar 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
8:20 am Celldex Therapeutics promotes SVP Richard Wright to the newly created position of Chief... Jul 01 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer Jul 01 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer Jul 01 2015
Celldex Cancer Vaccine May Get Fast-Tracked Jul 01 2015
Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog Jun 30 2015
Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of... Jun 29 2015
Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of... Jun 29 2015
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jun 11 2015
Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind Jun 05 2015
Celldex Glioblastoma Vaccine Hits Phase II Primary Endpoint - Analyst Blog Jun 02 2015
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate Jun 02 2015
An Immunotherapy To Treat Brain Cancer Rises In The Wake Of A Public Loss Jun 02 2015
Preliminary Transcript of CLDX conference call or presentation 1-Jun-15 12:00pm GMT Jun 01 2015
Celldex vaccine helps brain cancer patients live longer -study May 31 2015
Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma... May 31 2015
ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients May 31 2015
Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma... May 31 2015
Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK